Loading…

Multicenter validation of the PREDICT score for prediction of local recurrence after total mesorectal excision of rectal cancer

Background Total mesorectal excision (TME) is the gold standard treatment for rectal cancer. Although TME has managed to decrease the rates of local recurrence after rectal cancer resection, local recurrence is still recorded at varying rates. The present study aimed to validate the PREDICT score in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2022-09, Vol.126 (4), p.772-780
Main Authors: Emile, Sameh H., Madbouly, Khaled M., Elfeki, Hossam, Shalaby, Mostafa, Sakr, Ahmad, Zuhdy, Mohammad, Metwally, Islam H., Abdelkhalek, Mohamed
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Total mesorectal excision (TME) is the gold standard treatment for rectal cancer. Although TME has managed to decrease the rates of local recurrence after rectal cancer resection, local recurrence is still recorded at varying rates. The present study aimed to validate the PREDICT score in the prediction of local recurrence of rectal cancer after TME with curative intent. Methods This was a retrospective multicenter study on patients with nonmetastatic low or middle rectal cancer who underwent TME. The total PREDICT score was calculated for every patient and related to the onset of local recurrence. According to the final score, patients were allocated to one of three risk groups: low, moderate, and high, and the rates of local recurrence in each group were calculated and compared. Results The present study included 262 patients (50.4% males) with a mean age of 47.1 years. The overall local recurrence rate was 12.6%. 29.4% of patients were in the low‐risk group, 63.7% in the moderate‐risk group, and 6.9% in the high‐risk group. The local recurrence rate was 3.9% (95% confidence interval [CI]: 0.8–10.9) in the low‐risk group, 13.2% (95% CI: 8.4–19.3) in the moderate risk group, and 44.4% (95% CI: 21.5–69.2) in the high‐risk group (p 
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.26978